)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Blueprint Medicines (BPMC) investor relations material
Blueprint Medicines The Citizens JMP Life Sciences Conference 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.The Citizens JMP Life Sciences Conference 2025 summary7 May, 2025
Company overview and strategic focus
Blueprint Medicines has evolved from an oncology heritage to focus on diseases related to mast cell biology, with a strong emphasis on systemic mastocytosis (SM) and type 2 inflammatory diseases.
AYVAKIT, their lead commercial product, is approved in three indications: a subtype of GIST, advanced SM, and indolent SM (ISM), with ISM representing the largest market opportunity.
The company is in a strong financial position, self-sustaining, and expects significant revenue growth driven by AYVAKIT and its expanding pipeline.
Blueprint leverages a sophisticated data-driven sales approach and targeted digital campaigns to expand prescriber and patient engagement.
Ongoing investment in discovery and external partnerships continues to fuel pipeline expansion and innovation.
Financial outlook and growth drivers
2025 revenue guidance is $700–720 million, with AYVAKIT expected to reach $2 billion in global revenue by 2030, primarily from ISM.
The total franchise opportunity, including next-generation programs like elenestinib, is projected at over $4 billion.
U.S. is expected to contribute 70–80% of peak global revenues.
Market penetration assumptions are conservative, with $2 billion achievable by treating a minority (~6,000) of diagnosed U.S. patients.
Over $900 million in cash supports ongoing operations and pipeline development.
Commercial strategy and market expansion
Growth pillars include expanding the base of experienced prescribers, direct-to-consumer digital outreach, and peer-to-peer patient programs.
Recurring revenue is supported by long therapy duration, with patients typically staying on AYVAKIT for three or more years.
International expansion is underway, with Germany as the first commercial ISM market outside the U.S.
Blueprint invests in improved diagnostics and works with key opinion leaders to increase SM diagnosis rates, which have grown 20% over the past 4–5 years.
The company maintains disciplined spending, focusing on targeted digital campaigns rather than broad, costly advertising.
What's driving diagnosed SM patient growth?
Detail BLU-808's differentiation vs biologics.
How will Blueprint expand its pipeline?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Blueprint Medicines Corp. is a biopharmaceutical company focused on developing targeted therapies for genomically defined cancers and rare diseases. The company utilizes precision medicine approaches to design small-molecule drugs that inhibit specific genetic drivers of disease. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage